Skip to content
Screener

D&A at other companies

IAR
Integra LifeSciencesIART
$38.14M+1.2%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$86K-16.5%
iRadimed logo
iRadimedIRMD
$455K+135%
iRhythm Holdings, Inc. logo
iRhythm Holdings, Inc.IRTC
$5.22M+2.3%
ICU Medical logo
ICU MedicalICUI
$49.61M-0.1%
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$76M+4.1%

Other financials

Income statement

See full
Revenue$28.1M+32.5%
Gross profit$25.9M+38.8%
Operating income-$20.0M-33.6%
Net income-$19.3M-41.2%
EPS (diluted)-$0.51-34.2%

Balance sheet

See full
Cash & equivalents$32.7M-18.6%
Total debt$21.9M+1.7%
Total equity$128.3M-25.5%
Total assets$166.3M-19.9%

Cash flow

See full
Operating cash flow-$12.9M-70.8%
CapEx$17.0K-76.1%
Free cash flow-$12.9M-69.4%

Valuation

See full
Market cap$713.7M+50.8%
Enterprise value$702.95M+54.6%
P/S+0.9×

Profitability

See full
Gross margin88.9%+1.1pp
Operating margin-68.6%+1.5pp
Net margin-64.7%+0.9pp
FCF margin-53.7%+4.4pp

Returns & leverage

See full
Return on equity-43.9%
Debt / equity0.2×0.0×
Current ratio9.2×-4.1×

Where this comes from

Reported directly by CeriBell, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: CeriBell, Inc.’s 10-Q, filed August 10, 2026. Open the filing →

Filed
Aug 10, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342574

FAQ

What is CeriBell, Inc.'s D&A?
CeriBell, Inc. (CBLL) reported D&A of $245K in Q2 2026.
How has CeriBell, Inc.'s D&A changed year-over-year?
CeriBell, Inc.'s D&A decreased by 24.4% year-over-year, from $324K to $245K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about CeriBell, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude